Marine-derived anticancer agents: clinical benefits, innovative mechanisms, and new targets
Pereira, B.; Evdokimov, M.; Lefranc, F.; Valentao, P.; Kornienko, A.; Pereira, M.; Andrade, B.; Gomes, M. (2019). Marine-derived anticancer agents: clinical benefits, innovative mechanisms, and new targets. Mar. Drugs 17(6): 329. https://dx.doi.org/10.3390/md17060329
In: Marine Drugs. Molecular Diversity Preservation International (MDPI): Basel. ISSN 1660-3397; e-ISSN 1660-3397, more
|   |
| Keyword |
|
| Author keywords |
cytarabine; trabectedin; eribulin; brentuximab vedotin; plitidepsin;lurbinectedin; plinabulin; marizomib; plocabulin; antibody-drugconjugates |
| Authors | | Top |
- Pereira, R.B.
- Evdokimov, N.M.
- Lefranc, F.
- Valentão, P.
|
- Kornienko, A.
- Pereira, D.M.
- Andrade, P.B.
- Gomes, N.G.M.
|
|
| Abstract |
The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer. |
|
